Heartflow Highlights Strong Growth, Plaque Analysis Reimbursement, and Future Market Expansion in Investor Presentation

summarizeSummary

Heartflow presented a positive business update, showcasing strong financial performance, significant market adoption, and key product milestones, including reimbursement for its Plaque Analysis.

check_boxKey Events

• Strong Financial Performance

  Reported $162 million in LTM 3Q25 revenue, with 3Q25 FFRCT base business revenue growing 41% year-over-year, and LTM 3Q25 non-GAAP gross margin at 76%.

• Plaque Analysis Reimbursement Secured

  Heartflow Plaque Analysis received a Category 1 CPT code effective January 1, 2026, with over 70% U.S. covered lives, significantly de-risking a key growth driver.

• Expanding Market Adoption

  The U.S. installed base grew to 1,465 accounts in 2025, with 489 accounts adopting Plaque Analysis as of January 1, 2026.

• Future Growth Drivers

  The company projects a $6 billion mid-term U.S. TAM expansion into targeted asymptomatic markets through three ongoing RCTs.

auto_awesomeAnalysis

Heartflow's investor presentation outlines significant progress in its AI-powered coronary artery disease platform. Key highlights include robust revenue growth, expanding gross margins, and critical advancements in product reimbursement, particularly for its Plaque Analysis. The company's strategic roadmap for market expansion into asymptomatic populations, supported by ongoing clinical trials, indicates substantial long-term growth potential.